04:27 AM EDT, 06/03/2024 (MT Newswires) -- Gilead Sciences ( GILD ) and Arcus Biosciences ( RCUS ) said on Sunday data from Cohort B of Phase 1b/2 study evaluating its experimental combination therapy of etrumadenant, zimberelimab, and chemotherapy could meaningfully improve clinical outcomes for people with metastatic colorectal cancer who have failed at least two prior treatments.

The companies said the safety profiles of the combination therapies have been in line with those of each individual molecule.

Etrumadenant and zimberelimab are investigational and not yet approved for by any regulatory authority for any use.

Price: 64.24, Change: -0.03, Percent Change: -0.05